These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 33995308)

  • 1. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor
    Shionoya K; Yamasaki M; Iwanami S; Ito Y; Fukushi S; Ohashi H; Saso W; Tanaka T; Aoki S; Kuramochi K; Iwami S; Takahashi Y; Suzuki T; Muramatsu M; Takeda M; Wakita T; Watashi K
    Front Microbiol; 2021; 12():651403. PubMed ID: 33995308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.
    Ohashi H; Watashi K; Saso W; Shionoya K; Iwanami S; Hirokawa T; Shirai T; Kanaya S; Ito Y; Kim KS; Nomura T; Suzuki T; Nishioka K; Ando S; Ejima K; Koizumi Y; Tanaka T; Aoki S; Kuramochi K; Suzuki T; Hashiguchi T; Maenaka K; Matano T; Muramatsu M; Saijo M; Aihara K; Iwami S; Takeda M; McKeating JA; Wakita T
    iScience; 2021 Apr; 24(4):102367. PubMed ID: 33817567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.
    Sacramento CQ; Fintelman-Rodrigues N; Dias SSG; Temerozo JR; Da Silva APD; da Silva CS; Blanco C; Ferreira AC; Mattos M; Soares VC; Pereira-Dutra F; Miranda MD; Barreto-Vieira DF; da Silva MAN; Santos SS; Torres M; Chaves OA; Rajoli RKR; Paccanaro A; Owen A; Bou-Habib DC; Bozza PT; Souza TML
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2.
    Gendrot M; Jardot P; Delandre O; Boxberger M; Andreani J; Duflot I; Le Bideau M; Mosnier J; Fonta I; Hutter S; La Scola B; Pradines B
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
    Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.
    Gendrot M; Andreani J; Boxberger M; Jardot P; Fonta I; Le Bideau M; Duflot I; Mosnier J; Rolland C; Bogreau H; Hutter S; La Scola B; Pradines B
    Travel Med Infect Dis; 2020; 37():101873. PubMed ID: 32916297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing old drugs as antiviral agents for coronaviruses.
    Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
    Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro.
    Holwerda M; V'kovski P; Wider M; Thiel V; Dijkman R
    Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33256227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.
    Olaleye OA; Kaur M; Onyenaka CC
    bioRxiv; 2020 Sep; ():. PubMed ID: 32995775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication.
    Nakajima S; Ohashi H; Akazawa D; Torii S; Suzuki R; Fukuhara T; Watashi K
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins.
    Balasubramaniam M; Shmookler Reis RJ
    ChemRxiv; 2020 Apr; ():. PubMed ID: 32511290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir.
    Kongsomros S; Suksatu A; Kanjanasirirat P; Manopwisedjaroen S; Prasongtanakij S; Jearawuttanakul K; Borwornpinyo S; Hongeng S; Thitithanyanont A; Chutipongtanate S
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
    Rodon J; Muñoz-Basagoiti J; Perez-Zsolt D; Noguera-Julian M; Paredes R; Mateu L; Quiñones C; Perez C; Erkizia I; Blanco I; Valencia A; Guallar V; Carrillo J; Blanco J; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N
    Front Pharmacol; 2021; 12():646676. PubMed ID: 33841165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters.
    Roy Chattopadhyay N; Chatterjee K; Banerjee A; Choudhuri T
    Virusdisease; 2020 Dec; 31(4):479-489. PubMed ID: 33200085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.